K D Lettinga1, S Weijer, P Speelman, J M Prins, T Van Der Poll, A Verbon. 1. Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. k.d.Lettinga@amc.uva.nl
Abstract
BACKGROUND: Legionella pneumophila, a Gram negative intracellular pathogen, causes Legionnaires' disease (LD). Interferon (IFN)-gamma is important for host defence against L pneumophila so reduced IFN-gamma production capacity and/or responsiveness might render humans more susceptible to infection with L pneumophila. METHODS: Seventy seven patients who suffered from LD after a point source outbreak one year earlier participated in the study. Whole blood was incubated with non-specific stimuli (lipopolysaccharide (LPS) or interleukin (IL)-12) or specific stimuli (viable or heat killed L pneumophila) to evaluate IFN-gamma production, and with IFN-gamma to evaluate IFN-gamma responsiveness. Expression of complement receptor 3 on monocytes was determined by flow cytometry. Thirty seven companions who were also exposed but had not developed LD served as controls. RESULTS: Patients released less IFN-gamma than controls in response to stimulation with LPS (mean (SE) 393 (58) pg/ml v 914 (178) pg/ml; p=0.001) and IL-12 (96 (14) pg/ml v 177 (41) pg/ml; p=0.058). IFN-gamma responsiveness, measured by release of IFN-gamma inducible protein (IP)-10, tumour necrosis factor alpha, IL-12 production capacity, and monocyte expression of complement receptor 3, did not differ between patients and controls. IFN-gamma release after stimulation with LPS and IP-10 release after stimulation with IFN-gamma were weakly associated with severity of LD in the former patient group (rho=-0.3, p=0.011 and rho=-0.3, p=0.037, respectively). CONCLUSION: These results suggest that impaired IFN-gamma production may contribute to susceptibility to L pneumophila infection.
BACKGROUND: Legionella pneumophila, a Gram negative intracellular pathogen, causes Legionnaires' disease (LD). Interferon (IFN)-gamma is important for host defence against L pneumophila so reduced IFN-gamma production capacity and/or responsiveness might render humans more susceptible to infection with L pneumophila. METHODS: Seventy seven patients who suffered from LD after a point source outbreak one year earlier participated in the study. Whole blood was incubated with non-specific stimuli (lipopolysaccharide (LPS) or interleukin (IL)-12) or specific stimuli (viable or heat killed L pneumophila) to evaluate IFN-gamma production, and with IFN-gamma to evaluate IFN-gamma responsiveness. Expression of complement receptor 3 on monocytes was determined by flow cytometry. Thirty seven companions who were also exposed but had not developed LD served as controls. RESULTS:Patients released less IFN-gamma than controls in response to stimulation with LPS (mean (SE) 393 (58) pg/ml v 914 (178) pg/ml; p=0.001) and IL-12 (96 (14) pg/ml v 177 (41) pg/ml; p=0.058). IFN-gamma responsiveness, measured by release of IFN-gamma inducible protein (IP)-10, tumour necrosis factor alpha, IL-12 production capacity, and monocyte expression of complement receptor 3, did not differ between patients and controls. IFN-gamma release after stimulation with LPS and IP-10 release after stimulation with IFN-gamma were weakly associated with severity of LD in the former patient group (rho=-0.3, p=0.011 and rho=-0.3, p=0.037, respectively). CONCLUSION: These results suggest that impaired IFN-gamma production may contribute to susceptibility to L pneumophila infection.
Authors: M S Niederman; L A Mandell; A Anzueto; J B Bass; W A Broughton; G D Campbell; N Dean; T File; M J Fine; P A Gross; F Martinez; T J Marrie; J F Plouffe; J Ramirez; G A Sarosi; A Torres; R Wilson; V L Yu Journal: Am J Respir Crit Care Med Date: 2001-06 Impact factor: 21.405
Authors: H C Boshuizen; S E Neppelenbroek; H van Vliet; J F Schellekens; J W den Boer; M F Peeters; M A Conyn-van Spaendonck Journal: J Infect Dis Date: 2001-07-16 Impact factor: 5.226
Authors: K Tateda; T A Moore; J C Deng; M W Newstead; X Zeng; A Matsukawa; M S Swanson; K Yamaguchi; T J Standiford Journal: J Immunol Date: 2001-03-01 Impact factor: 5.422
Authors: F N Lauw; A J Simpson; J M Prins; S J van Deventer; W Chaowagul; N J White; T van der Poll Journal: Infect Immun Date: 2000-07 Impact factor: 3.441
Authors: J K Brieland; C Jackson; S Hurst; D Loebenberg; T Muchamuel; R Debets; R Kastelein; T Churakova; J Abrams; R Hare; A O'Garra Journal: Infect Immun Date: 2000-12 Impact factor: 3.441
Authors: Jeroen W Den Boer; Ed P F Yzerman; Joop Schellekens; Kamilla D Lettinga; Hendriek C Boshuizen; Jim E Van Steenbergen; Arnold Bosman; Susan Van den Hof; Hans A Van Vliet; Marcel F Peeters; Ruud J Van Ketel; Peter Speelman; Jacob L Kool; Marina A E Conyn-Van Spaendonck Journal: Emerg Infect Dis Date: 2002-01 Impact factor: 6.883
Authors: Jeroen L A Pennings; Marjolein N T Kremers; Hennie M Hodemaekers; Julia C J P Hagenaars; Olivier H J Koning; Nicole H M Renders; Mirjam H A Hermans; Arja de Klerk; Daan W Notermans; Peter C Wever; Riny Janssen Journal: Clin Vaccine Immunol Date: 2015-04-29
Authors: George M Solomon; Carla Frederick; Shaoyan Zhang; Amit Gaggar; Tom Harris; Bradford A Woodworth; Chad Steele; Steven M Rowe Journal: PLoS One Date: 2013-08-16 Impact factor: 3.240
Authors: Benjamin H Schott; Alejandro L Antonia; Liuyang Wang; Kelly J Pittman; Barbara S Sixt; Alyson B Barnes; Raphael H Valdivia; Dennis C Ko Journal: Sci Rep Date: 2020-10-26 Impact factor: 4.996